All News

Found 65,177 articles

• Bellerophon Therapeutics Announces Proposed Public Offering of Common Stock

  5/18/2020

  Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”) today announced that it intends to offer and sell shares of its common stock in an underwritten registered public offering.

• Akers Biosciences Closes $4.8 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

  5/18/2020

  Akers Biosciences, Inc. (the “Company”) (NASDAQ: AKER), a developer of rapid health information technologies, today announced the closing of its previously announced registered direct offering of an aggregate of 1,366,856 shares of the Company’s common stock, at a purchase price of $3.53 per share priced at-the-market under Nasdaq rules.

• Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus

  5/18/2020

  After two doses all participants evaluated to date across the 25 µg and 100 µg dose cohorts seroconverted with binding antibody levels at or above levels seen in convalescent sera mRNA-1273 elicited neutralizing antibody titer levels in all eight initial participants across the 25 µg and 100 µg dose cohorts, reaching or exceeding neutralizing antibody titers generally seen in convalescent sera mRNA-1273 was generally safe and well tolerated

• Centivax Antibodies Neutralize the Pandemic Coronavirus, Independently Confirmed by Three Research Laboratories (USAMRIID, Stanford, and UTMB/GNL)

  5/18/2020

  Centivax Inc, the therapeutics spin-out of Contract Research Organization Distributed Bio Inc, announced a significant advance in their mission to develop an optimized antibody therapeutic to treat COVID-19.

• Portola Pharmaceuticals Announces Virtual 2020 Annual Stockholder Meeting

  5/18/2020

  Portola Pharmaceuticals, Inc.® (NASDAQ: PTLA) today announced that, due to the public health impact of the coronavirus (COVID-19) pandemic and to prioritize the health and well-being of stockholders, employees and other meeting participants, the location and format of its 2020 Annual Stockholder Meeting

• Todos Medical Announces First Commercial Sale of COVID-19 Antibody Tests

  5/18/2020

  Sub-distributor has network of state and local government clients seeking testing solutions   Return to Church program being initiated in Orlando, Fla. area REHOVOT, Israel, SINGAPORE and NEW YORK, May 18, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF) , an  in vitro  diagnostics company focused on the distribution of a comprehensive suite of solutions for the screening and diagnosis of COVID-19 and the development of blood tests for the early detection of

• ORYZON Announces Enrollment of First Patient in ESCAPE: a Phase II Clinical Trial with Vafidemstat in Severely Ill COVID-19 PatientsESCAPE study to recruit 40 patients

  5/18/2020

  Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the enrollment of the first patient in its Phase II clinical trial with vafidemstat in seriously ill COVID-19 patients. The study, named ESCAPE (Nº EudraCT: 2020-001618-39), is an open-label, randomized, double arm Phas

• BioLife Solutions Promotes Marcus Schulz to Vice President, Global Sales

  5/18/2020

   BioLife Solutions, Inc. (NASDAQ: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of a portfolio of best-in-class bioproduction tools for cell and gene therapies, today announced the promotion of Marcus Schulz to the position of Vice President, Global Sales

• Turning Point Therapeutics Announces Pricing of $325 Million Public Offering of Common Stock

  5/18/2020

  Turning Point Therapeutics, Inc. (Nasdaq: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the pricing of its previously announced underwritten public offering of 5,416,667 shares of its common stock at a price to the public of $60.00 per share.

• Cellect Biotechnology's ApoGraft™ to Empower Cellular Treatment of COVID-19 Related Pulmonary Diseases

  5/18/2020

  Signs Development Agreement with International Consortium; Royalties Will be Based on Commercialization of Future Products Clinical Results in GvHD Studies May be Beneficial in COVID-19 and CAR-T Cytokine Storm manifestations   [18-May-2020]   TEL AVIV, Israel , May 18, 2020 /PRNewswire/ -- Cellect Biotechnology Ltd. (NASDAQ: APOP), a developer of innovative tec

• MagnaCare and BioReference Laboratories Bring COVID-19 Antibody Testing to New York Labor Groups

  5/18/2020

  MagnaCare today announced a collaboration with BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), to bring COVID-19 antibody testing to their Labor clients in the New York metropolitan area. Through this collaborati

• Thermo Fisher Scientific's Support of COVID-19 Response Continues to Expand with U.S. Government Contract for Products Used in Sample Collection

  5/18/2020

  Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has received a contract from the U.S. government to provide highly specialized viral transport media (VTM) for COVID-19 sample collection. The VTM is used during collection of patient samples for proper transport to laboratories that can test for the presence of the virus.

• Zebra Medical Vision Secures its 5th FDA Clearance, Making Its Vertebral Compression Fractures AI Solution Available in the U.S.

  5/18/2020

  Zebra-Med is the first AI startup securing FDA clearance for a population-health product helping health providers close the COVID-19-induced care gaps by identifying more patients at risk of osteoporosis, which costs $52B in the U.S. alone. Zebra-Med has also received its fourth U.S. patent in its bone health series, measuring potential risk for vertebral fractures KIBBUTZ SHEFAYIM, Israel--( BUSINESS WIRE )-- Zebra Medical Vision , the deep-learning

• VeChain and I-Dante Partnered to Create Blockchain Enabled Medical Data Management Platform for Healthcare Provider in Cyprus

  5/18/2020

  With more than 4.6 million infections, 300 thousand deaths and counting caused by COVID-19, national governments, healthcare systems regardless of region and continent have been scrambling to respond to it, and the pandemic has highlighted the increasing demand for digital technologies to replace our old way of communication.

• Hoth Therapeutics Procures Full Licensing Rights for BioLexa Platform, Atopic Dermatitis Treatment

  5/18/2020

   Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced today that the company has obtained exclusive worldwide licensing rights to the BioLexa Platform, a proprietary, patented antimicrobial therapy focused on treating atopic derm

• VistaGen Submits PH94B Phase 2A Study Protocol for Treatment of Adjustment Disorder with Anxiety Related to the COVID-19 Pandemic through U.S. FDA's Coronavirus Treatment Acceleration Program (CTAP)

  5/18/2020

  VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety and depression, as well as certain central nervous system (CNS) diseases and disorders with

• Early Research Doubts Benefit of COVID-19 Drug Treatment

  5/18/2020

  Hospitalized COVID-19 patients receiving hydroxychloroquine and/or azithromycin fared no better than patients receiving neither drug, according to a retrospective study of 1,438 patients just published in the Journal of the American Medical Association (JAMA). 

• AACC Issues Recommendations on the Use of COVID-19 Antibody Tests

  5/18/2020

  To ensure the proper use of antibody testing for the novel coronavirus, AACC today issued a public statement detailing the role these tests should play in the management of COVID-19 patients and in the development of public health policy

• Aegea Biotechnologies, Inc. Announces the Issuance of 7 Additional Key U.S. Patents Relating to its Core, Next Generation Nucleic Acid Clinical Diagnostic Technologies and COVID-19 Test Development

  5/18/2020

  Aegea Biotechnologies, Inc. ( “Aegea”) ( www.aegeabiotech.com), a biotechnology company focusing on the development and commercialization of next generation nucleic acid clinical diagnostic technologies, announces the issuance of 7 additional key US patents related to its core next generation nucleic acid clinical diagnostic technologies, including applications related to COVID-19 diagnostic testing under the c

• New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients

  5/18/2020

  Biogen Inc. (Nasdaq: BIIB) today announced additional data from the SPINRAZA (nusinersen) clinical development program that further demonstrate the sustained efficacy and longer-term safety of SPINRAZA in a broad range of patients with spinal muscular atrophy (SMA)